Medtronic PLC 10-Q quarterly reports

Medtronic plc reported increased net sales in the third quarter and first nine months of fiscal year 2026, driven by strong segment growth, but net income and diluted EPS declined.

Medtronic plc announced robust financial results for the second quarter and first half of fiscal year 2026, driven by strong segment performance and progress on its Diabetes business separation.

Medtronic plc announced an 8% increase in net sales and a 13% rise in operating profit for Q1 FY26, alongside a significant patent litigation victory and progress on its Diabetes business separation.

Medtronic's Q3 2025 results reveal growth in net sales and earnings per share, driven by strong performance in key segments.

Medtronic's second quarter fiscal year 2025 results show a 5% increase in net sales and diluted earnings per share of $0.99, driven by growth in several key business segments.

Medtronic's first quarter of fiscal year 2025 saw a 3% increase in net sales, driven by strong performance in Diabetes and Neuromodulation, despite a negative impact from Italian payback accruals.

Medtronic's Q3 fiscal 2024 results show a 5% increase in revenue, driven by growth in Cardiovascular, Neuroscience, and Diabetes segments.